|
Drugs for treatment of helminthiasis of animals Drug for treatment of helminthiasis of animals comprises albendazole sulphoxide, butafosfan and water for injections with the following mass ratio of components, %: albendazole sulphoxide (n-[6-(propan-1-sulphinyl)-1H-1,3-benzodiazole-2-yl] methoxy carboximide acid) 5.0-10.0; butafosfan (1-butylamino-1-methyl) ethylphosphonic acid) 10.0-20.0; water for injections - the rest. |
|
Method of treating patients with intestinal disbacteriosis Hepatotropic preparation Hepaguard Active is administered in a dose of 1 capsule 3 times a day at mealtimes for 28-30 days. |
|
Method involves a twice-yearly concomitant use of medicinal products: intramuscular injections of polyoxidonium in a dose of 0.1 mg/kg of child's body weight every 1-2 days for 10 days; oral administration of eslidin in a dose of 1 capsule 2 times a day in the children aged between 3 to 7 years, and in a dose of 1 capsule 3 times a day in the children older than 7 years, for 21 days. |
|
Nucleoside inhibitors of rna-polymerase hcv ns5b, methods for production and use thereof Invention relates to C3alkyl ethers (S)-2-{[(2R,3R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4,4-difluoro-3-hydroxy-tetrahydrofuran-2-ylmethoxy]phenoxy-phosphoryl amino}-propionic acid of general formula 1 and pharmaceutically acceptable salts thereof. The compounds have properties of nucleoside inhibitors of RNA-polymerase HCV NS5B and can be used to treat and prevent viral diseases such as hepatitis C. In formula R1 is C1-C4alkyl. A pharmaceutical composition based on a compound of formula 1 may further contain an inhibitor of RNA-polymerase NS5A, such as Ribavirin, Ribamidin or methyl ether hydrochloride [(S)-1-((S)-2-{5-[4-(4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)pyrrolidin-2-yl-3H-imidazol-4-yl]buta-1,3-diinyl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-carbonyl)-2-methyl-propyl]}-carbamic acid (AV-4025). |
|
Derivative of diphenyl sulphide, and pharmaceutical product containing it as active ingredient Invention relates to derivative of diphenyl sulphide, that can be used in medicine as antagonist of S1P3 receptor of common formula (1) |
|
Method for reducing multi-drug resistance with using inositol tripyrophosphate Invention refers to medicine, namely oncology, and can be used for treating cancer. That is ensured by administering a therapeutically effective amount of inositol tripyrophosphate (ITPP) and a therapeutically effective amount of a chemotherapeutic agent specified in a microtube-targeted agent (docetaxel, paclitaxel), a DNA-intercalating agent (cisplatin, doxorubicin) and a nucleoside metabolic inhibitor (gemcitabine, kalecitabine) into an individual in need thereof. The ITPP is administered before the chemotherapeutic agent has been administered. |
|
Method of preventing leukaemia in young cattle Ligfol, phosprenil and E-selenium are prescribed during 6 months to heifers of 6 months of age, free of bovine leukaemia virus according to the results of serological (RID) and molecular biological (PCR) studies in combination, which are administered intramuscularly according to the following scheme: ligfol and phosprenil at a dose of 5 ml/head once a month, E-selenium three times with an interval of 2 months at a dose of 3 ml/head, increasing the dose each time by 1 ml/head. |
|
Method of determining duration of treatment of active forms of otosclerosis To determine density of otospongiosis focuses computer tomography of temporal bones with densitometry is carried out. Treatment duration is determined on the basis of obtained values of density. If density of otospongiosis focuses is less than 300 units HU, 4 courses of complex inactivating therapy are carried out. If density is 300-600 HU units -2 courses, if density is 600-900 units HU - 1 course. Duration of one course constitutes 3 months. During a year not more than two courses of therapy are carried out. Course of inactivating complex therapy includes intake of the following medications: bisphosphonates, sodium fluoride, calcium carbonate and vitamin D3. As bisphosphonates medication Bonviva is applied. |
|
|
Substituted (2r,3r,5r)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidates Present invention relates to a novel (2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate of general formula I or a stereoisomer or a pharmaceutically acceptable salt thereof, having properties of nucleoside inihibitors of RNA polymerase NS5B of the hepatitis C virus. The invention also relates to a method of producing compounds, pharmaceutical compositions and a medicinal agent based on said compounds. In general formula 1 , R1 is hydrogen, (CH3)2[(CH3)3C]Si, C2-C6acyl, optionally substituted with a benzyloxy group, NR5R6 group, wherein R5 and R6 are independently hydrogen or C1-C4alkyl; 1-pyrrol-2-ylcarbonyl, piperidin-3-ylcarbonyl or piperidin-4-ylcarbonyl; R2 and R3 are F or R2 is F or OH and R3 is CH3; R4 is hydrogen or methyl; Ar is phenyl, pyridyl or naphthyl, where the phenyl, pyridyl or naphthyl is optionally substituted with at least one of C1-3alkyl, C2-4alkenyl, C2-4alkynyl, C1-3alkoxy, F, Cl, Br, I, nitro, cyano, -N(C1-3alkyl)2; Pm is 2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl or 4-(4-amino-2-oxo-2H-pyrimidin-1-yl), wherein the amino group is optionally substituted with 1-pyrrol-2-ylcarbonyl, piperidin-3-ylcarbonyl, piperidin-4-ylcarbonyl or a C(O)R8 radical, where R8 is C1-C4alkyl, optionally substituted with a NR6R7 group, where R6 and R7 are independently hydrogen or C1-C4alkyl; C1-3alkoxy, optionally substituted with a phenyl; X is O or N-R9, where R9 is C1-C4alkyl, optionally substituted with OH or OCH3; n=1, 2 or 3. |
|
Invention refers to betulinic acid derivatives, producing them and using for cancer. For producing derivatives of formulas |
|
Method for non-invasive treatment of legg's disease Orthopaedic unload is accompanied with prescribing a therapeutic diet promoting weight reduction and adequate feeding of calcium and vitamins C, D, E, K.That is combined with the oral administration of Fosamax® tablets 70 mg once a week for 6 months, Arthrodarin® capsules 50 mg in the morning and evening for 4-6 months and nasal sprayings of Miacalcic® 200 International Units/day in cycles of 2 weeks every 2 weeks for 4-6 months. What is also used is Milgamma® solution for intramuscular injections 2 ml a day, at least 10 times, with a pause of 1 day. Alflutop® 2 ml a day is injected intramuscularly daily within at least 20 days. That is combined with a therapeutic course including 8-10 therapeutic sessions each of which consists of the two stages of procedures following each other. The first of this stages involve the successive one-day abdominal decompression of the lower body from the waist down, pneumocompression massage of legs, manual and vacuum massages. The exposure segments are: hip joints - lateral surface of hips, gluteal region and paravertebral area L2-L5, cervical segment - paravertebral area C7-T1 and sacral bone. A preferred pause between the above procedures is no more than 10-15 minutes. Thereafter, the first stage of the therapeutic session is completed by conducting a hirudotherapy with the use of no more than 8 medicinal leeches per one session to be placed on the cervical paravertebral area C7-T1 and lumbar paravertebral area L2-L5, sacral bone, tail bone, abdomen within the liver, lower abdomen, painful hip segments and/or segments discoloured after the massage. Each therapeutic session is completed by successive procedures of the second stage with a pause of at least 3 days. A magnetic therapy and a barolasertherapy cover the segments: hip joints - lateral surface of hips, gluteal region and paravertebral areas L2-L5. A phonophoresis with the used of karipain gel covers the gluteal, knee and hip segments. Thereafter, 24 hours later the therapeutic session is repeated depending on the patient's state no more than 10 times. That is followed by doing therapeutic physical exercises in the swimming pool within at least 10 days. Kartalax® peptide preparation 1-2 ml in the concentration of at least 100 mcg in 1 ml diluted together with Tymalin® 10 mg is administered daily once a day for 10 days. After the injections are completed, peptide Vezugen® capsules 0.2 g are orally administered in the morning and in the evening 10-15 minutes before meals for 30 days. After the continuous and single course of Fosamax® and nasal sprayings of Miacalcic® are completed, 1-2 months later Osteogenon® tablets 830 mg are administered daily in a dose of 2-4 tablets 2 times a day, and Arthrodarin® capsules are also taken in a dose of 50 mg in the morning and in the evening for 4-6 months. The oral administration of the last-mentioned two preparations is repeated at least three months later. |
|
|
Compositions and methods of treating cancer Invention refers to pyrroloquinolinyl pyrrolidine-2,5-diones of formula IVa, IVb, Va or Vb possessing the properties of cancer cell inhibitor properties, to a based pharmaceutical composition, and to a method of treating using them. In general formulas |
|
Drug substance of polyprenylphosphates and beta-sitosterol and method for preparing it Invention represents a method for preparing a drug substance of polyprenylphosphates and beta-sitosterol consisting in pre-mixing polyprenylphosphates and sorbitol in a mortar, a size of which fits the total volume of the mixed substances. Between a wall and/or a bottom of the mortar and the introduced polyprenylphosphates, there is a layer of sorbitol; the blended mixture of the polyprenylphosphates in sorbitol is homogenised. Sorbitol, a dry mixture of polyprenylphosphates in sorbitol in a ratio of 1:8 and beta-sitosterol are added into a homogeniser, and pulsed homogenisation is performed for 10 minutes. The homogenisation is performed at a rotation rate of 500-700 rpm for 4 minutes, 1000-1200 rpm for 2 minutes and then 500-600 rpm for 4 minutes; the rotation rate variation requires a pause of 20 minutes. Each pause of the process is followed by the intensive agitation of a mixture cup; the prepared powder is sieved at a mesh size of 20 mcm; if a sieving weight makes less than 0.1% of the weight of the loaded ingredients; the homogenisation process is terminated. |
|
Pharmaceutical composition in the form of ointments for treatment of mastitis in cows comprises n-tetradecyltributylphosphonium bromide as active ingredient and petrolatum as an excipient at the ratio of 1:2000. |
|
Composition, containing crystallisation-inhibiting substances Invention relates to a composition, adapted for intravenous introduction, intended for the treatment or prevention of pathological processes of crystallisation or calcification in a person, subjected to dialysis. The composition contains inositol phosphate and/or its pharmaceutically acceptable salt, with a dose of inositol phosphate and/or its salt constituting from 1 nmol/kg to 0.1 mil/kg. The invention also relates to a combined method of treatment, including the intravenous introduction of the said composition of the dialysis liquid simultaneously. |
|
Antifungal therapeutic preparation in suppositories for children Invention represents an antifungal preparation in suppositories for children containing recombinant human interferon 2α and fluconazole, wherein lysozyme, Licopid and dimephosphone are additionally introduced. |
|
![Alkyl2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2h-pyrimidine-1-yl)- -hydroxy- tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-proptonates, nucleoside inhibitors of rna-polymerase hcv ns5b, methods for producing and using them](http://img.russianpatents.com/img_data/1186/11868031-s.jpg)
|
Invention refers to new compounds of general formula 1 or their stereoisomers or pharmaceutically acceptable salts possessing the properties of inhibitors of RNA polymerase HCV NS5B, and to methods for producing them. In general formula 1 R1 represents C1-C4alkyl; R2 and R3 represents fluorine, or R2 represents fluorine, while R3 represents methyl; one of R4 and R5 represents hydrogen, and the other of R4 and R5 represents C1-C6acyl optionally substituted by α-aminoacyl specified in a group containing (dimethylamino)acetyl, 1-tert-butoxycarbonylamino-2-methyl-propylcarbonyl, 1-methylpyrrolidine-2-carbonyl, 1-methylpiperidine-3-carbonyl and 1-methylpiperidine-4-carbonyl, R6 represents hydrogen, methyl, methoxy and halogen. |
|
Therapeutic combination containing lung surfactant and steroid What is presented is a group of inventions involving: using poractant alfa in a dose of 100 to 200 mg/kg in a combination with beclomethasone dipropionate in a dose of 0.6 to 0.8 mg/kg for preventing bronchopulmonary dysplasia (BPD) (versions) for producing a therapeutic agent for preventing BPD, a respective pharmaceutical composition and a kit for the same application. |
|
|
Pharmaceutical compositions containing bisphosphonate derivatives and high doses of cholecalciferol Present invention refers to pharmaceutics and represents a pharmaceutical composition for preventing and treating osteoporosis, administered once a month and containing: (a) cholecalciferol granules, wherein (i) cholecalciferol in an amount of 24000-50000 IU; (ii) one or more ingredients specified in tocopherol acetate, butylated hydroxy toluene and butylated hydroxy anisole as a first stabilizing agent; and (iii) a binding agent adsorbed on microcrystalline cellulose, (b) mannitol as a second stabilizing agent, and (c) risedronic acid or its salt or ibandronic acid or its salt. |
|
|
Salts of isophosphoramide yprite and its analogues Present invention refers to a crystalline compound effective for treating hyperproliferative diseases and having formula (I) , |
|
Method for supporting treatment in large joint replacement Invention refers to medicine, namely traumatology, orthopaedics, and can be used for supporting treatment in large joint replacement. That is ensured by determining a volume of involved joint contracture six months before the operation. That is followed by X-ray and magnetic resonant examination of the involved and collateral joints to specify their state. Besides, a quality of the bone tissue is assessed by osteodensitometry. If observing changes in the bone tissue quality, the complex of the drug therapy is added with the preparations Bivalos and Calcemin. A pain syndrome intensity is assessed by the visual analogue scale three months before the operation. That is followed by the complex therapy aiming at optimising the state of extremity joints with added local injection therapy (LIT). That is ensured by preliminary exposing the biologically active periarticular zones in the proximal and distal direction from the involved joint to the focused infrared laser light. A mixture containing solutions of the therapeutic preparations: chondroprotectors, Contrykal, Lidocaine, vitamin B12 is injected into the same zones. Besides, Arthrofoon is administered for the whole preoperative period. If the pain syndrome intensity is less than 4 points, Arthrofoon is administered in a dose of 4 tablets a day. If the intensity value is more than 4 points, the preparation is administered in a dose of 8 tablets a day in a complex with a short course of a non-steroidal anti-inflammatory preparations and a chondroprotector. The replacement operation is immediately followed by fixing a collateral joint with an orthesis for the period of 3 months. The complex of the postoperative supporting therapy started three weeks after the operation is added with a single intravenous introduction of the preparation Aklasta, the preparation Arthrofoon in a dose of 4 tablets a day for three months, alpha calcidole and Calcemin continuously. A pectoral girdle of the extremities is reinforced by means of an individually specified set of therapeutic exercises and electric walking myostimulation. The LIT of the collateral joint is performed three months after the operation. If observing a degenerative process in the adjacent joints, the LIT is performed alternatively in these regions. Vasodilators, chondroprotectors, and the preparation Milgamma are administered with underlying LIT. If observing psychoemotional changes in the patient, the preparation Tenoten is additionally administered. A postoperative medication regimen, including the LIT is repeated 3-4 times every 6 months. |
|
|
Medication for reduction of hepatitis c virus reproduction Invention represents a medication for reduction of the hepatitis C virus reproduction, which contains at least one polyprenyl phosphate or polyprenyl pyrophosphate with a number of isoprene units from 9 to 20, mainly from 13 to 18, either a mixture of different polyprenyl phosphates or different polyprenyl pyrophosphates, or a mixture of different polyprenyl phosphates and polyprenyl pyrophosphates with a specified number of isoprene units in a weight ratio from 5:1 to 20:1. |
|
Method for immune correction with api-phytocomposition Immune deficiency is modulated in laboratory animals by single cyclophosphan administration in a dose of 200 mg/kg of body weight (the first day of an experiment). The immune deficiency is corrected by an api-phytocomposition in the form of an aqueous suspension of honey, pollen, propolis, purple Echinacea extract in a ratio of 10:1:1:2. The composition is administered into the laboratory animal intragastrically (through a probe) in a dose of 200 mg/kg daily for 10 days on the second day of the experiment. |
|
|
Osteo- and vertebroplasty are performed; introducing bone cement follows introducing a composition prepared as follows: Veroklast 4 mg dissolved in water for injections 1 ml with the prepared solution mixed with the osteoplastic material KollapAp-G 2 ml in the form of gel into a lytic lesion. |
|
|
Compositions and methods of skin care Invention relates to biomedical compositions and methods of treating skin-affecting diseases, disorders and states. |
|
Suppositories comprise active substance triphenyl-(3,5-di-tret-butyl-4-hydroxybenzyl) phosphonium bromide in an amount of 1%. As the pharmaceutically acceptable carriers the suppositories comprise "polyethylene glycol-6000" (30%), higher fatty alcohols C16-C21 (0.6%), calcium stearate (0.8%) and sucrose (42.8%), foaming agents contain citric acid (10%), sodium bicarbonate (14.8%). |
|
Invention refers to new pyrido[2,3-b]pyrazine derivatives of general formula (I), wherein radicals and symbols are specified in the patent claim. The given compounds inhibit the enzymes ERK, ERK1, ERK2, PI3K, PI3Kalpha, PI3Kbeta, PI3Kgamma, PI3Kdelta, PI3K-C2alpha, PI3K-C2beta, PI3K-Vps34p. |
|
Method for correction vascular microelement oversaving accompanying atherosclerosis Method refers to medicine, namely to therapy, and concerns the correction of vascular microelement oversaving accompanying atherosclerosis. That is ensured by administering effective amounts of bisphosphonates - either xydiphone, or mediphone, or zoledronate. |
|
Phosphonium salt preparation for treating mastitis in veterinary medicine Invention relates to veterinary science, namely to obstetrics and gynaecology. A preparation for treating and preventing sub-clinical, clinical, acute and chronic mastitis in farm and domestic animals contains an active substance that is - triphenyl-(3,5-di-tert-butyl-4-hydroxybenzyl)phosphonium bromide and a pharmaceutically acceptable carrier that is Vaseline in ratio 1:2000. |
|
Invention refers to an anticancer compound of formula . |
|
Method of treating skeletal complications in patients with lytic long bone metastases Intramedullary osteosynthesis is followed by a bone grafting of a lytic lesion with using a composition prepared as follows: Veroklast dry concentrate 4 mg is dissolved in water for injections 1 ml; the prepared solution is mixed with Kollapan granules 2 g and incubated at room temperature until absorbed completely. |
|
|
Agent for treating coccidiosis in veterinary science Invention refers to veterinary science. An agent for treating diseases caused by various species of protozoan of the sub-circle Protozoa, type Apicomlexa, class Sporozoa, order Coccidiida, family Eimeriidae, characterized by the fact that its active substance is triphenyl-(3,5-di-tert-butyl-4-hydroxybenzyl)phosphonium bromide. The agent may be used as a coccidiostatic preparation 10 mg/kg (at the active substance) in a single dose. |
|
Invention relates to dialkyl(2-methyl-4-oxopent-2-yl) phosphine oxide pyridinoyl hydrazones (Ia-c) for treating tuberculosis, which can be used in medicine and veterinary: la Py-4-Py, R=Et; Ib Py=4-Py, R=Pr; 1c Py=3-Py, R=Et. |
|
Invention refers to veterinary science, and may be used in veterinary science in treating parasitic skin diseases in animals caused by itch mites. An agent for itch mite treatment in veterinary science contains a quaternary phosphonium salt, substituted dinitrobenzofuraxan, xymedon hydrochloride and dimethylsulphoxide in weight ratio 0.1:1:10:100. The treatment uses 1% emulsion of the given agent in dimethylsulphoxide. |
|
Invention relates to bis-phosphorylated 2,6-di-tert-butyl-4-methylphenol (1-3) derivatives of general formula I, which can be used in medicine and veterinary (I) n=2(1); n=3(2); n=6(3). |
|
Triphenyl-(3,5-di-tert-butyl-4-hydroxybenzyl)phosphonium bromide possessing antihelmintic activity Invention refers to a new anti-nematode drug representing triphenyl-(3,5-di-tret-butyl-4-hydroxybenzyl)phosphonium bromide which may be used in veterinary science. |
|
Anti-cancer agents with benzophenanthridine structure and preparations containing them There are presented: using benzophenanthridine alkaloid salts for preparing therapeutic agents for treating tumours, wherein the alkaloid salt is found in the form luteic, phosphatidic or hyaluronic acid, the benzophenanthridine alkaloid salt with phosphatidic acid or hyaluronic acid, and a based pharmaceutical composition for treating tumours. |
|
|
Agent for low-turnover metabolic bone disease in patients with chronic renal insufficiency Invention refers to medicine, namely nephrology, and may be used for administering alendronate as an agent for low-turnover metabolic bone disease in the patients suffering chronic renal insufficiency (CRI). |
|
|
Use of 2,4-diaminopyrimidines for treating atherosclerosis Invention refers to medicine, particularly to pharmaceutical treatment of atherosclerosis and an associated risk of cardiovascular diseases. That is ensured by using the effective amount of a Syk-kinase inhibitor representing N4-(2,2-dimethyl-4-[(dihydrophosphonoxy)methyl]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluor-K2-(3,4,5-trimethoxyphenyl)-2,4-diamonopyrimidines and a salt thereof. |
|
Invention refers to pharmaceutics and medicine, and concerns an agent for treating or disinfecting of alkyl, aryl-(3,5-di-tert-butyl-4-hydroxybenzyl)phosphonium bromides and nitrates of general formula , having simultaneous bactericidal, fungicidal and antioxidant activity at low concentrations, high thermal stability and low toxicity, which can find application in medicine and veterinary science. |
|
Agent for low-metabolic bone disease in patients with chronic renal insufficiency Invention refers to medicine, namely nephrology, and may be used for administering ibandronate as an agent for low-metabolic bone disease in the patients suffering chronic renal insufficiency (CRI). |
|
|
Present invention refers to 2-amino-1-((phosphonoxy)methyl)-3-(3-((4-((2-pyridinyloxy)methyl)phenyl)methyl)-5-isoxazolyl)pyridinium of formula: and salts thereof effective as an antimycotic agent, and to pharmaceutical compositions and therapeutic agents based on it and the use thereof in treating mycotic diseases. |
|
Phosphonic acid derivatives and use thereof as p2y12 receptor antagonists Invention refers to derivatives of Ice formula and the use thereof in treating the diseases associated with thrombocyte aggregation ICE', wherein P(O)R5R8 is specified in R1 is specified in phenyl; W is specified in a bond, -O-, -NR3-; R2 is specified in alkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, phenyl, heterocyclyl, or heteroaryl, alkoxycarbonyl alkyl, carboxyalkyl or phenyl alkyl; R3 is specified in hydrogen or alkyl; or R2 and R3 form a ring together with a nitrogen atom; Ra is specified in hydrogen or methyl; R4 is specified in alkoxy; n is from 0 to 3; m is from 0 to 1; V is specified in a bond and phenyl; R5 and R8 are specified in hydroxyl, phenyloxy, benzyloxy, -O-(CHR6)-O-C(=O)-R7, -O-(CHR6)-O-C(=O)-O-R7, -O-(CHR6)-C(=O)-O-R9, -NH-(CHR10)-C(=O)-O-R9, -NH-C(CH3)2-C(=O)-O-R9; q is equal to 2; R6 is specified in hydrogen and alkyl; R7 is specified in alkyl or cycloalkyl; R9 is specified in alkyl; R10 is specified in hydrogen, alkyl, phenyl or benzyl; and R11 is specified in hydrogen, alkyl or alkoxy. |
|
Method of increasing mineral density of bone tissue Invention relates to medicine, namely to orthopedics and restorative medicine, and can be used for increasing mineral density of bone tissue. For this purpose human body is subjected to impact of uniformly accelerated physical loading created by movement of simulator vibration platform in three mutually perpendicular planes with increase of intensity of physical loading and mode. Alendronic acid in dose 70 mg 1 time per week, calcium preparations in dose 1000 mg per day, vitamin D in dose 800 IU per day, as well as functional foodstuff "Samarskiy zdorovyak" No 83 in volume 90 g per day are additionally introduced. Treatment course constitutes 24 weeks. |
|
|
Group of inventions relates to medicine and deals with pharmaceutical combination of receptor S1P agonist with accompanying agent for treatment of demyelinating diseases except optic nerve neuritis. In claimed pharmaceutical combination agonist of S1P receptor is 2-amino-2-[2-(4-octylphenyl)ethyl]pronane-1,3-diol (FTY720) in free form, in form of pharmaceutically acceptable salt or (FTY720) phosphate, and accompanying agent is interferon, in particular interferon β, or mTOR inhibitor, in particular rapamycin, 40-O-(2-hydroxyethyl)rapamycin or other rapamycin derivative. Claimed is method of treatment, relief or delay of progress of demyelinating disease except optic nerve neuritis, in particular of disseminated sclerosis and Guillain-Barre syndrome, which includes introduction of said combination. Also claimed is application of said combination for manufacturing respective medication. |
|
Invention refers to a formulation and a pharmaceutical composition for providing more effective transdermal delivery of alkaloids containing alkaloid having a basic nitrile group and a mixture of mono-tocopheryl phosphate and di-tocopheryl phosphate. The invention also refers to using alkaloid having the basic nitrile group and a method for providing more effective transdermal delivery of alkaloid. |
|
Oral pharmaceutical composition Pharmaceutical composition applicable for oral administration contains an S1P receptor agonist and mannitol with the composition representing a solid dosage form. Mannitol has a particle specific surface area 1 to 7 m2/g, and the S1P receptor agonist is specified from 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol (FTY720), its pharmaceutically acceptable salt and FTY720-phosphate. |
|
Method for preparing pharmaceutical composition Method for preparing a pharmaceutical composition consists in mixing an S1P receptor agonist - 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or its pharmaceutically acceptable salt with sugar alcohols; the mixture is milled and/or granulated, and then mixed with an oil agent. The method under invention is implemented on high-speed automated equipment and enables producing the compositions with high-level distribution uniformity of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or its pharmaceutically acceptable salt in the composition applicable for oral administration of said S1P receptor agonist. |
|
Use of tri-substituted glycerol compounds for treating hematological malignant tumours There are offered: use of the tri-substituted glycerol compounds of formula (I) in preparing a therapeutic agent with said therapeutic agent applied with at least one other therapeutic agent containing one or more additional active ingredients specified in a group consisting of antimetabolites, herbal alkaloids, topoisomerase II inhibitors, proteasome inhibitors; related combination and an in vitro method for determining sensitivity of hematological malignant tumours to a combination of the therapeutic agents as specified in the present invention. |
|
Invention relates to field of veterinary. Composition includes n-tetradecyl(tri-n-butyl)phosphonium-chloride and 5,7-bis-(m-nitroanilino)-4,6-dinitrobenzofuroxane as active components and glucose as auxiliary substance with weight ratio of active components 1:10. |
Another patent 2551184.